Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

802.83
-16.5500-2.02%
Post-market: 802.11-0.7190-0.09%19:59 EDT
Volume:3.98M
Turnover:3.17B
Market Cap:759.84B
PE:52.50
High:804.44
Open:788.96
Low:783.85
Close:819.38
52wk High:935.63
52wk Low:623.78
Shares:946.46M
Float Shares:945.00M
Volume Ratio:1.64
T/O Rate:0.42%
Dividend:5.80
Dividend Rate:0.72%
EPS(TTM):15.29
EPS(LYR):11.76
ROE:86.29%
ROA:16.55%
PB:41.58
PE(LYR):68.28

Loading ...

Chesapeake Sells 9,900 Eli Lilly (LLY) Shares Worth $7.7 Million

Motley Fool
·
Oct 17

Eli Lilly’s Latest Study on Obesity Treatment: A Promising Update

TIPRANKS
·
Oct 17

Eli Lilly and Company to Release Third-Quarter 2025 Financial Results

Reuters
·
Oct 16

Eli Lilly Price Target Maintained With a $948.00/Share by Guggenheim

Dow Jones
·
Oct 16

Did Viking Therapeutics Just Say "Checkmate" to Eli Lilly?

Motley Fool
·
Oct 16

Guggenheim Remains a Buy on Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 16

BREAKINGVIEWS-Slashing US drug prices would come at a cost: podcast

Reuters
·
Oct 16

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Oct 16

NOVO NORDISK TO INFORM AFFECTED U.S. EMPLOYEES ACROSS RANGE OF DEPARTMENTS THIS WEEK AND NEXT ABOUT LAYOFFS, COMPANY EMAIL AND SOURCES SAY

THOMSON REUTERS
·
Oct 15

Eli Lilly's (LLY.US) Oral Weight Loss Drug Achieves Success in Phase III Trials, Plans for Market Application Next Year

Stock News
·
Oct 15

Nektar litigation hearing against Lilly delayed, says B. Riley

TIPRANKS
·
Oct 15

Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials

Dow Jones
·
Oct 15

Eli Lilly's Oral GLP-1 Drug Orforglipron Shows Superior Results in Phase 3 Type 2 Diabetes Trials

Reuters
·
Oct 15

Lilly's Oral Glp-1, Orforglipron, Demonstrated Superior Glycemic Control in Two Successful Phase 3 Trials, Reconfirming Its Potential as a Foundational Treatment in Type 2 Diabetes

THOMSON REUTERS
·
Oct 15

Eli Lilly - to Submit Orforglipron for Type 2 Diabetes in 2026

THOMSON REUTERS
·
Oct 15

Eli Lilly - Orforglipron Lowers a1c by 2.1% With Insulin Glargine in Achieve-5

THOMSON REUTERS
·
Oct 15

Eli Lilly - Orforglipron Lowers a1c by up to 1.7% in Achieve-2

THOMSON REUTERS
·
Oct 15

Major Shareholder Sells Millions in Eli Lilly Stock!

TIPRANKS
·
Oct 15

1 Reason Eli Lilly (LLY) Is One of the Best Healthcare Stocks You Can Buy Today

Motley Fool
·
Oct 15

Lilly Endowment Inc. Reports Disposal of Common Shares of Eli Lilly and Company

Reuters
·
Oct 15